Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 12;10(5):054115.
doi: 10.1063/1.4964716. eCollection 2016 Sep.

Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets

Affiliations

Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets

S Sarkar et al. Biomicrofluidics. .

Abstract

Cell-cell communication mediates immune responses to physiological stimuli at local and systemic levels. Intercellular communication occurs via a direct contact between cells as well as by secretory contact-independent mechanisms. However, there are few existing methods that allow quantitative resolution of contact-dependent and independent cellular processes in a rapid, precisely controlled, and dynamic format. This study utilizes a high-throughput microfluidic droplet array platform to analyze cell-cell interaction and effector functions at single cell level. Controlled encapsulation of distinct heterotypic cell pairs was achieved in a single-step cell loading process. Dynamic analysis of dendritic cell (DC)-T cell interactions demonstrated marked heterogeneity in the type of contact and duration. Non-stimulated DCs and T cells interacted less frequently and more transiently while antigen and chemokine-loaded DCs and T cells depicted highly stable interactions in addition to transient and sequential contact. The effector function of CD8+ T cells was assessed via cytolysis of multiple myeloma cell line. Variable cell conjugation periods and killing time were detected irrespective of the activation of T cells, although activated T cells delivered significantly higher cytotoxicity. T cell alloreactivity against the target cells was partially mediated by secretion of interferon gamma, which was abrogated by the addition of a neutralizing antibody. These results suggest that the droplet array-based microfluidic platform is a powerful technique for dynamic phenotypic screening and potentially applicable for evaluation of novel cell-based immunotherapeutic agents.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Cell co-encapsulation in droplet microfluidic platform. (a) Schematic of integrated droplet generation and a microarray device. (b) Generation of nanoliter droplets. (c) Droplets loaded in a microarray for stable docking. (d) Morphology of single DC and T cell in the droplet. Inset: Magnified image of dendrite extension by DC. (e) Cellular exocytosis observed in the droplet. Inset: Magnified image of vesicles secreted by DC at 4 h. Scale bar: 20 μm. (F) Representative mean velocity profiles of one T cell, DC, and RPMI-8226 cell in the droplet. (g) A decrease in velocity as cells near each other and form conjugate. The onset of contact period is indicated by ♦. RPMI-8226 cell death occurred at 240 min and the complex dissociated rapidly.
FIG. 2.
FIG. 2.
Dynamic monitoring of interaction between stimulated DC and CD3+ T cells in microfluidic droplets. (a) DCs were pulsed with OVA-FITC (100 μg/ml, 16 h) and CCL21 (25 ng/ml, 2 h) and co-encapsulated with untreated T cells in droplets. OVA-FITC expression on the DC surface is indicated by arrowheads. T cells are labeled with CMTPX tracker (red), which is transferred to the DCs over time. A series of time-lapse images of the same droplet is shown over a period of 1 h. Images were obtained every 5 min. Scale bar: 20 μm. (b) Analysis of the types of interaction between DC and T cell: no interaction over a period of 5 h (-), continuous interaction for 5 h and discontinuous interaction defined by short periods of attachment and detachment. DCs were pre-treated with OVA-FITC and CCL21 (n = 227 cell pairs) or untreated (n = 100). (c) Cells undergoing a discontinuous interaction were further categorized into transient (≤10 min of contact) and stable (≥10min) interactions. (d) Distribution of contact times between DC and T cells (outliers are indicated). The data are represented as mean ± SEM of n = 3 independent experiments. P < 0.05 is indicated by *.
FIG. 3.
FIG. 3.
(a) Interaction between multiple cells in droplets. DCs (green) were treated with OVA-FITC and CCL21. The CD3+ T cells were untreated and labeled with CMTPX (red) tracker. The panels (phase, fluorescent, and overlay) depict DC and T cells at various time points (representative of n = 30 droplets). Scale bar: 20 μm. (b) Number of contacts made between treated DC-T cell pairs (1:1 ratio). The data are represented as mean ± SEM from three independent experiments.
FIG. 4.
FIG. 4.
Interaction between CD8+ T cells and target cells (RPMI-8226) in droplets. (a) Lysis and death of target cell in contact with CD8+ T cell. Target cells (green) were labeled with Calcein AM. Scale bar: 50 μm. The T cells were not labeled. (b) % of target cell death mediated by T cells (n = 3, mean ± SEM). P < 0.05 is indicated by *. A total of n = 292, 210, and 144 cells were quantified in Control, PMA/Ionomycin-treated, and PMA/Ionomycin/IFN-γ-treatment groups, respectively. (c) Comparison of time required by PMA/Ionomycin-treated T cells to promote target cell death. A threshold of 200 min was set for distinguishing fast vs. slow kill. (d) Effect of the presence/absence of IFN-γ antibody on rapid target death. Cell numbers (n) used for analysis in this representative experiment are indicated. (e) Number of contacts made between activated T cell-target cell pairs in a representative experiment. n: 104, 98, and 53 for Control, PMA/Ionomycin-treated, and PMA/Ionomycin/IFN-γ-treated cells, respectively.

References

    1. Davis D. M., Nat. Rev. Immunol. , 543 (2009).10.1038/nri2602 - DOI - PubMed
    1. Beltman J. B., Marée A. F., Lynch J. N., Miller M. J., and de Boer R. J., J. Exp. Med. , 771 (2007).10.1084/jem.20061278 - DOI - PMC - PubMed
    1. Bousso P., Nat. Rev. Immunol. , 675 (2008).10.1038/nri2379 - DOI - PubMed
    1. Lanzavecchia A. and Sallusto F., Science , 92 (2000).10.1126/science.290.5489.92 - DOI - PubMed
    1. Salmon H., Franciszkiewicz K., Damotte D., Dieu-Nosjean M. C., Validire P., Trautmann A., Mami-Chouaib F., and Donnadieu E., J. Clin. Invest. , 899 (2012).10.1172/JCI45817 - DOI - PMC - PubMed